



WE CLAIM:

~~1. A compound of Formula (I):~~



~~wherein:~~

~~ring C is selected from:~~



~~wherein the wavy lines (~~~~) indicate the points of attachment of the C₁-carbon to the carbonyl of C(O)-OR¹, and the C₂-carbon to L;~~

~~L is a bond, CH₂, CF₂, O, NR¹, S, S(=O), C(=O), CH₂-Q, or Q-CH₂; wherein Q is O, NR¹, or S;~~

~~R¹ is hydrogen, C₁₋₄-alkyl, C₃₋₆-cycloalkyl, phenyl, or benzyl; wherein the C₁₋₄-alkyl is optionally substituted with hydroxycarbonyl, alkoxycarbonyl, hydroxycarbonylalkyl, or alkylcarbonyloxy; and the phenyl group alone or as a part of the benzyl group is optionally substituted with one or two groups selected from halo and haloalkoxy;~~

~~Ring A is C₃₋₈-cycloalkyl, C₈₋₁₁-spirocycloalkyl, 5-8 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thienyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, pyridyl, indolyl, benzothiazolyl, quinoliny, isoquinoliny, indoliny, isoindoliny, tetrahydroquinoliny, dihydroisoquinoliny, tetrahydroisoquinoliny, 2,3-dihydrobenzo[b][1,4]dioxiny, or tetrahydro-methanonaphthaleny;~~

~~Ring B is present or not present; wherein:~~

~~when Ring B is present, then Ring A is optionally substituted with one or two groups independently selected from halo, alkyl, alkoxy, cyano, hydroxy, haloalkoxy, (cycloalkyl)alkoxy, and cycloalkyl;~~

~~when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:~~

~~(i) one or two R^{AA}-groups;~~

~~(ii) 2 halo groups when L is other than O;~~

~~(iii) 2 halo groups when L is O, and R² and R³ are not hydrogen or alkyl;~~

- (iv) ~~one halo group when L is CH₂NR¹;~~
- (v) ~~one halo group and one group selected from the group consisting of haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, and (phenyl)alkoxy, when L is bond, O, S, or S(=O), wherein the phenyl is optionally substituted with halo, cyano, haloalkyl, or haloalkoxy; or~~
- (vi) ~~one cyano group and one (phenyl)alkoxy group, when L is bond or O, wherein the phenyl as part of the (phenyl)alkoxy group is optionally substituted with halo or haloalkoxy;~~

~~when Ring B is not present and Ring A is other than phenyl, then~~

- (i) ~~Ring A is substituted with one or two R^{AB} groups or~~
- (ii) ~~Ring A is unsubstituted, wherein:~~
 - 1) ~~when Ring A is unsubstituted tetrahydroquinoliny, then L is a bond;~~
 - 2) ~~when Ring A is unsubstituted 2,3-dihydrobenzo[b][1,4]dioxiny, then L is O;~~
 - 3) ~~when Ring A is unsubstituted tetrahydronaphthyl, then L is O, and R¹ is not hydrogen or ethyl; or~~
 - 4) ~~when Ring A is unsubstituted spirocycloalkyl, then L is O, S, or CH₂S;~~

~~each R^{AA} is independently alkyl; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; phenoxy optionally substituted with one or two halo groups; or alkylcarbonylaminoalkoxy;~~

~~each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; or phenoxy optionally substituted with one or two halo groups;~~

~~Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with 1, 2, or 3 R^B groups;~~

~~each R^B is independently halo; cyano; alkyl; hydroxyalkyl; alkylsulfonyl; aminosulfonyl; alkylaminosulfonyl; dialkylaminosulfonyl; haloalkyl; alkoxy; aminoalkoxy; alkylaminoalkoxy; dialkylaminoalkoxy; hydroxyalkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylaminocarbonyl; dialkylaminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; cycloalkyloxy; (cycloalkyl)alkoxy wherein the cycloalkyl group is optionally substituted with hydroxyalkyl; cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with one or two groups independently selected from halo, alkyl, and alkylcarbonyl; (5-6 membered heterocycloalkyl-one)alkyl; 5-6 membered heterocycloalkyl-one; (heterocycloalkyl)alkyl; heterocycloalkylcarbonyl; or~~

~~5-6 membered heteroaryl optionally substituted with one group selected from alkyl, hydroxyalkyl, (hydroxycycloalkyl)alkyl, alkoxyalkyl, and hydroxycycloalkyl;~~

~~R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxy carbonyl, phenylcarbonyloxy, aminocarbonyloxy, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy carbonyloxy, cycloalkylcarbonyloxy, N(R^{1A})C(O)R^{1B}, N(R^{1A})C(O)OR^{1B}, or N(R^{1A})C(O)NR^{1B}R^{1C}; wherein R^{1A}, R^{1B}, and R^{1C} are each independently hydrogen or C₁₋₆ alkyl;~~

~~R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy carbonyl;~~

~~provided:~~

- ~~i. when L is S or CH₂, and Ring A is phenyl other than phenyl substituted with (cycloalkyl)alkoxy, then Ring B cannot be halo substituted phenyl;~~
- ~~ii. when L is O, Ring A is phenyl, and Ring B is not present, then R^{AA} cannot be alkyl;~~
- ~~iii. when L is O, Ring A is phenyl substituted with 1 R^{AA}, and Ring B is not present, then R^{AA} cannot be meta substituted trifluoromethyl;~~
- ~~iv. when L is O, Ring A is phenyl, Ring B is not present, and R¹ is ethyl, then R^{AA} cannot be trifluoromethoxy;~~
- ~~v. when L is bond, Ring A is other than phenyl, Ring B is not present, and R¹ is H, then R^{AB} cannot be methyl, and~~
- ~~vi. when L is NH, Ring A is pyridyl, indolyl, or indolinyl, and Ring B is not present, then R^{AB} cannot be alkyl; and~~

~~optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.~~

~~2. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein~~

~~L is a bond, CH₂, CF₂, O, NR^L, S, C(=O), CH₂-Q, or Q-CH₂; wherein Q is O, NR^L, or S;~~

~~R^L is hydrogen or C₁₋₄ alkyl optionally substituted with hydroxycarbonyl, alkoxy carbonyl, hydroxycarbonylalkyl, or alkylcarbonyloxy;~~

~~Ring A is C₅₋₇-cycloalkyl, 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, phenyl, naphthyl, indanyl, tetrahydronaphthalinyl, dihydronaphthalinyl, pyridyl, indolyl, benzothiazolyl, quinoliny, isoquinoliny, indoliny, isoindoliny, tetrahydroquinoliny, dihydroisoquinoliny, or tetrahydro-methanonaphthaleny;~~

~~Ring B is present or not present; wherein:~~

~~when Ring B is present, then Ring A is optionally substituted with one or two halo, alkyl, alkoxy, or haloalkoxy;~~

~~when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:~~

~~—— (i) one or two R^{AA}-groups, or (ii) 2 halo groups when L is other than O;~~

~~when Ring B is not present and Ring A is other than phenyl, then Ring A is substituted with one or two R^{AB}-groups;~~

~~each R^{AA} is independently alkyl, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;~~

~~each R^{AB} is independently halo, alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;~~

~~Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;~~

~~each R^B is independantly halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylcarbonyl, alkoxyalkoxy, —— alkylcarbonylaminoalkoxy, —— cycloalkyl, —— (cycloalkyl)alkyl, cycloalkyloxy, —— (cycloalkyl)alkoxy, —— cycloalkylcarbonyl, —— cycloalkylcarbonyloxy, heterocycloalkyl optionally substituted with alkyl or alkylcarbonyl, (5-6 membered heterocycloalkyl-one)alkyl, (heterocycloalkyl)alkyl, or heterocycloalkylcarbonyl;~~

~~R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; where W is alkyl substituted with amino, —— alkylamino, —— dialkylamino, —— alkylcarbonyloxy, —— alkoxycarbonyl, —— or phenylcarbonyloxy; and~~

~~R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, —— or heterocycloalkylcarbonyloxy —— optionally substituted with alkoxycarbonyl.~~

~~3. —— The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 2, wherein~~

~~Ring B is present; wherein Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;~~

each R^B is independently halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylcarbonyl, alkoxyalkoxy, alkylcarbonylaminoalkoxy, cycloalkyl, (cycloalkyl)alkyl, cycloalkyloxy, (cycloalkyl)alkoxy, cycloalkylcarbonyl, cycloalkylcarbonyloxy, heterocycloalkyl optionally substituted with alkyl or alkylcarbonyl, (5-6-membered heterocycloalkyl-one)alkyl, (heterocycloalkyl)alkyl, or heterocycloalkylcarbonyl; provided that when L is S and Ring A is phenyl, then Ring B is not halo-substituted phenyl.

4. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein

Ring A is C_{3-7} -cycloalkyl, C_{8-11} -spirocycloalkyl, 5-8-membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thienyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, pyridyl, indolyl, benzothiazolyl, quinolinyl, isoquinolinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, or tetrahydro-methanonaphthalenyl;

Ring B is present or not present; wherein:

when Ring B is present, then Ring A is optionally substituted with one or two groups selected from halo, alkyl, alkoxy, haloalkoxy, (cycloalkyl)alkoxy, and cycloalkyl;

when Ring B is not present and Ring A is other than phenyl, then

(i) Ring A is substituted with one or two R^{AB} -groups or

(ii) Ring A is unsubstituted, wherein:

1) when Ring A is unsubstituted tetrahydroquinolinyl, then L is bond;

2) when Ring A is unsubstituted 2,3-dihydrobenzo[b][1,4]dioxinyl, then L is O;

3) when Ring A is unsubstituted tetrahydronaphthyl, then L is O, and R^1 is not hydrogen or ethyl; or

4) when Ring A is unsubstituted spirocycloalkyl, then L is O or S;

each R^B is independently halo, cyano, alkyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, haloalkyl, alkoxy, haloalkoxy, alkylcarbonyl, alkoxyalkoxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylaminoalkoxy, cycloalkyl, (cycloalkyl)alkyl, cycloalkyloxy, (cycloalkyl)alkoxy, cycloalkylcarbonyl, cycloalkylcarbonyloxy, heterocycloalkyl optionally substituted with one or two groups independently selected from halo, alkyl, and alkylcarbonyl; (5-6-membered heterocycloalkyl-one)alkyl; 5-6-membered

heterocycloalkyl one; ~~—(heterocycloalkyl)alkyl;—heterocycloalkylcarbonyl;—or—5-6~~
membered heteroaryl.

5. ~~—The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically~~
acceptable salt of claim 1, wherein

Ring B is not present;

L is a bond, CH₂, CF₂, O, NR^L, S, C(=O), CH₂-Q, or Q-CH₂; wherein Q is O, NR^L, or S;

R^L is hydrogen or C₁₋₄-alkyl optionally substituted with hydroxycarbonyl, alkoxycarbonyl,
hydroxycarbonylalkyl, or alkylcarbonyloxy;

Ring A is C₅₋₇-cycloalkyl, 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl,
thiazolyl, phenyl, naphthyl, indanyl, tetrahydronaphthalinyl, dihydronaphthalinyl, pyridyl,
indolyl, ~~—benzothiazolyl,—quinolinyl,—isoquinolinyl,—indolinyl,—isoindolinyl,~~
tetrahydroquinolinyl, dihydroisoquinolinyl, or tetrahydro-methanonaphthalenyl;

wherein:

when Ring A is phenyl, then Ring A is substituted with:

~~—(i) one or two R^{AA} groups, or (ii) 2 halo groups when L is other than O;~~

when Ring A is other than phenyl, then Ring A is substituted with one or two R^{AB} groups;
each R^{AA} is independently alkyl, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or
phenoxy optionally substituted with one or two halo;

each R^{AB} is independently halo, alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy,
(cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;

R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; where W is alkyl substituted with
amino, ~~—alkylamino,—dialkylamino,—alkylcarbonyloxy,—alkoxycarbonyl,—or~~
phenylcarbonyloxy; and

R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl;
wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy,
cycloalkylcarbonyloxy, ~~—or—heterocycloalkylcarbonyloxy—optionally—substituted—~~with
alkoxycarbonyl.

6. ~~—The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically~~
acceptable salt of claim 5, wherein

Ring A is phenyl, naphthyl, indanyl, tetrahydronaphthalinyl, dihydronaphthalinyl, pyridyl,
benzothiazolyl, quinolinyl, isoquinolinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, or
dihydroisoquinolinyl;

wherein:

when Ring A is phenyl, then Ring A is substituted with:

—(i) one or two R^{AA} groups, or (ii) 2 halo groups when L is other than O;

when Ring A is other than phenyl, then Ring A is substituted with one or two R^{AB} groups;
each R^{AA} is independently haloalkoxy, cycloalkyloxy, or phenoxy optionally substituted with one or two halo;

each R^{AB} is independently halo, alkyl, alkoxy, or haloalkoxy;

R^1 is hydrogen, alkyl, cycloalkyl, or W; where W is alkyl substituted with alkylcarbonyloxy;
and

R^2 and R^3 are independently hydrogen or alkyl; wherein the alkyl is optionally substituted with alkylcarbonyloxy.

7. —The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein

Ring B is not present;

Ring A is C_{3-7} -cycloalkyl, C_{8-11} -spirocycloalkyl, 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, pyridyl, indolyl, benzothiazolyl, quinolinyl, isoquinolinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, or tetrahydro-methanonaphthalenyl;

wherein:

when Ring A is phenyl, then Ring A is substituted with:

(i) —one or two R^{AA} groups,

(ii) —2 halo groups when L is other than O;

(iii) —2 halo groups when L is O, and R^2 and R^3 are not hydrogen or alkyl,

(iv) —one halo group when L is CH_2NR^L , or

(v) —one halo group and one group selected from the group consisting of haloalkoxy, (cycloalkyl)alkoxy, and (phenyl)alkoxy, when L is bond, O or S,
wherein the phenyl is optionally substituted with halo;

when Ring A is other than phenyl, then

(i) —Ring A is substituted with one or two R^{AB} groups; or

(ii) —Ring A is unsubstituted, wherein:

1) —when Ring A is unsubstituted tetrahydroquinolinyl, then L is bond;

- 2) ~~when Ring A is unsubstituted 2,3-dihydrobenzo[b][1,4]dioxinyl, then L is O;~~
- 3) ~~when Ring A is unsubstituted tetrahydronaphthyl, then L is O, and R¹ is not hydrogen or ethyl; or~~
- 4) ~~when Ring A is unsubstituted spirocycloalkyl, then L is O or S.~~

8. ~~The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 7, wherein~~

~~Ring A is piperidinyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, pyridyl, quinoliny, isoquinolynyl, tetrahydroquinoliny, tetrahydroisoquinoliny, spiro[2.5]octane, spiro[4.5]decane, or spiro[5.5]undecane;~~

~~when Ring A is phenyl, then Ring A is substituted with:~~

- (i) ~~one or two R^{AA}-groups;~~
- (ii) ~~2 halo groups when L is other than O;~~
- (iii) ~~2 halo groups when L is O, and R² and R³ are not hydrogen or alkyl;~~
- (iv) ~~one halo group when L is CH₂NR^B, or~~
- (v) ~~one halo group and one group selected from the group consisting of haloalkoxy and (cycloalkyl)alkoxy, when L is bond, O or S;~~

~~each R^{AA} is independently haloalkyl, cycloalkyloxy, (cycloalkyl)alkoxy, or alkylcarbonylaminoalkoxy;~~

~~each R^{AB} is independently halo, alkyl, haloalkyl, or haloalkoxy;~~

~~R¹ is hydrogen, alkyl or W; wherein W is alkyl substituted with alkylcarbonyloxy;~~

~~R² and R³ are independently hydrogen or alkyl; wherein the alkyl is optionally substituted with cycloalkylcarbonyloxy or heterocycloalkylcarbonyloxy, wherein the heterocycloalkylcarbonyloxy optionally substituted with alkoxycarbonyl.~~

9. ~~The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein~~

~~Ring B is present;~~

~~Ring A is C₃₋₇-cycloalkyl, C₈₋₁₁-spirocycloalkyl, 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thienyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, pyridyl, indolyl, benzothiazolyl, quinoliny, isoquinoliny, indoliny, isoindoliny, tetrahydroquinoliny, dihydroisoquinoliny, tetrahydroisoquinoliny, 2,3-dihydrobenzo[b][1,4]dioxinyl, or tetrahydro-methanonaphthalenyl; wherein Ring A is~~

~~optionally substituted with one or two groups selected from halo, alkyl, alkoxy, and haloalkoxy;~~

~~Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B groups;~~

~~each R^B is independently halo; cyano; alkyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; — aminocarbonyl; — alkylcarbonylaminoalkoxy; — cycloalkyl; (cycloalkyl)alkyl; — cycloalkyloxy; — (cycloalkyl)alkoxy; — cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl; alkylcarbonyl — or — a — halo; — (5-6 membered — heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl.~~

~~10. — The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 9, wherein~~

~~L is bond, CH₂, CF₂, O, NR^L, S, CH₂-Q, or Q-CH₂; wherein Q is O, NR^L, or S;~~

~~R^L is hydrogen, C₁₋₄ alkyl, or benzyl, wherein the phenyl, as part of the benzyl group, is optionally substituted with haloalkoxy;~~

~~Ring A is C₃₋₇ cycloalkyl, 5-6 membered heterocycloalkyl, phenyl, or naphthyl, wherein Ring A is optionally substituted with halo or haloalkoxy;~~

~~Ring B is cycloalkyl, heterocycloalkyl, phenyl, tetrahydronaphthyl, tetrahydroquinolinyl, quinolinyl, or, isoquinolinyl; wherein each Ring B is optionally substituted with one or two R^B groups;~~


~~each R^B is independently halo; cyano; haloalkyl; haloalkoxy; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; — cycloalkyl; — (cycloalkyl)alkoxy; — heterocycloalkyl optionally substituted with 1 or 2 alkyl; alkylcarbonyl or halo; or (5-6 membered heterocycloalkyl-one)alkyl; and~~

~~R^L is hydrogen or W; wherein W is alkyl substituted with alkylcarbonyloxy, dialkylaminocarbonyloxy cycloalkylcarbonyloxy, or phenylcarbonyloxy.~~

~~11. — The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-10, wherein L is a bond, O, S, NR^L, CH₂-Q, or Q-CH₂; wherein Q is O, NR^L, or S.~~


~~12. — The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-11, wherein L is O or S.~~

13. ~~A compound of Formula (IV):~~



~~wherein:~~

~~Ring C is selected from:~~



~~wherein the wavy lines (~~~~~) indicate the points of attachment of the C₁-carbon to the carbonyl of C(O)-OR¹, and the C₂-carbon to N of NR^S;~~

~~R^S is hydrogen or C₁₋₄-alkyl optionally substituted with hydroxycarbonyl, alkoxycarbonyl, hydroxycarbonylalkyl, or alkylcarbonyloxy;~~

~~Ring A is C₅₋₇-cycloalkyl, 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, phenyl, naphthyl, indanyl, tetrahydronaphthalinyl, dihydronaphthalinyl, pyridyl, indolyl, benzothiazolyl, quinolinyl, isoquinolinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, dihydroisoquinolinyl, or tetrahydro-methanonaphthalenyl;~~

~~Ring B is present or not present; wherein:~~

~~when Ring B is present, then Ring A is optionally substituted with one or two halo, alkyl, alkoxy, or haloalkoxy;~~

~~when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:~~

~~(i) one or two R^{AA}-groups, or (ii) 2 halo-groups;~~

~~when Ring B is not present and Ring A is 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, naphthyl, indanyl, tetrahydronaphthalinyl, dihydronaphthalinyl, benzothiazolyl, quinolinyl, isoquinolinyl, isoindolinyl, tetrahydroquinolinyl, or dihydroisoquinolinyl, then Ring A is substituted with one or two R^{AB}-groups;~~

~~when Ring B is not present and Ring A is pyridyl, indolyl, or indolinyl, then Ring A is substituted with one or two R^{AC}-groups;~~

~~each R^{AA} is independently alkyl, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;~~

each R^{AB} is independently halo, alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;

each R^{AC} is independently halo, hydroxy, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;

Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B groups;


each R^B is independantly halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylcarbonyl, alkoxyalkoxy, alkylcarbonylaminoalkoxy, cycloalkyl, (cycloalkyl)alkyl, cycloalkyloxy, (cycloalkyl)alkoxy, —cycloalkylcarbonyl, —cycloalkylcarbonyloxy, —heterocycloalkyl optionally substituted with alkyl or alkylcarbonyl, (5-6 membered heterocycloalkyl-one)alkyl, (heterocycloalkyl)alkyl, or heterocycloalkylcarbonyl;

R^1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; where W is alkyl substituted with amino, —alkylamino, —dialkylamino, —alkylcarbonyloxy, —alkoxycarbonyl, —or phenylcarbonyloxy;

R^2 and R^3 are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxycarbonyl; and


optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.

14. — A compound of Formula (IV):



wherein:

Ring C is selected from:



wherein the wavy lines (—) indicate the points of attachment of the C_1 carbon to the carbonyl of $C(O)OR^1$, and the C_2 carbon to N of NR^1 ;

~~R¹ is hydrogen, C₁₋₄-alkyl, C₃₋₆-cycloalkyl, phenyl, or benzyl; wherein the C₁₋₄-alkyl is optionally substituted with hydroxycarbonyl, alkoxycarbonyl, hydroxycarbonylalkyl, or alkylcarbonyloxy; and the phenyl group alone or as a part of the benzyl group is optionally substituted with one or two groups selected from halo and haloalkoxy;~~

~~Ring A is C₃₋₇-cycloalkyl, C₈₋₁₁-spirocycloalkyl, 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, pyridyl, indolyl, benzothiazolyl, quinoliny, isoquinoliny, indoliny, isoindoliny, tetrahydroquinoliny, dihydroisoquinoliny, tetrahydroisoquinoliny, 2,3-dihydrobenzo[b][1,4]dioxiny, or tetrahydro-methanonaphthaleny;~~

~~Ring B is present or not present; wherein:~~

~~when Ring B is present, then Ring A is optionally substituted with one or two groups selected from halo, alkyl, alkoxy, and haloalkoxy;~~

~~when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:~~

- ~~—— (i) one or two R^{AA}-groups, or
(ii) 2 halo-groups;~~

~~when Ring B is not present and Ring A is 5-6 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, benzothiazolyl, quinoliny, isoquinoliny, isoindoliny, tetrahydroquinoliny, dihydroisoquinoliny, tetrahydroisoquinoliny, or 2,3-dihydrobenzo[b][1,4]dioxiny, then Ring A is substituted with one or two R^{AB}-groups;~~

~~when Ring B is not present and Ring A is C₃₋₇-cycloalkyl or C₈₋₁₁-spirocycloalkyl, then Ring A is optionally substituted with one or two R^{AB}-groups;~~

~~when Ring B is not present and Ring A is pyridyl, indolyl, or indoliny, then Ring A is substituted with one or two R^{AC}-groups;~~

~~each R^{AA} is independently alkyl; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; phenoxy optionally substituted with one or two halo; or alkylcarbonylaminoalkoxy;~~

~~each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; or phenoxy optionally substituted with one or two halo;~~

~~each R^{AC} is independently halo; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; or phenoxy optionally substituted with one or two halo;~~

~~Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;~~

~~each R^B is independently halo; cyano; alkyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl;~~

~~(cycloalkyl)alkyl; — cycloalkyloxy; — (cycloalkyl)alkoxy; — cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl — or — halo; — (5-6 membered — heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl;~~

~~R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, — alkylamino, — dialkylamino, — alkylcarbonyloxy, — alkoxy carbonyl, phenylcarbonyloxy, — aminocarbonyloxy, — alkylaminocarbonyloxy, dialkylaminocarbonyloxy, — alkoxy carbonyloxy, — cycloalkylcarbonyloxy, — N(R^{1A})C(O)R^{1B}, — N(R^{1A})C(O)OR^{1B}, or — N(R^{1A})C(O)NR^{1B}R^{1C}; wherein R^{1A}, R^{1B}, and R^{1C} are each independently hydrogen or C₁₋₆ alkyl;~~


~~R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy carbonyl; and~~

~~optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.~~

~~15. — The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-11 or 13-14, wherein R^L is hydrogen or C₁₋₄ alkyl.~~


~~16. — The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-11 or 13-15, wherein R^L is hydrogen.~~

~~17. — A compound of Formula (V):~~



~~wherein:~~

~~Ring C is selected from:~~



wherein the wavy lines () indicate the points of attachment of the C₁-carbon to the carbonyl of C(O)-OR¹, and the C₂-carbon to O;

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each is substituted with one or two ~~—R^{AB}—~~groups; provided

when Ring B is present, then Ring A is optionally substituted with one halo or alkyl;

when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:

—(i) one or two R^{AD}—groups, or (ii) two groups selected from chloro or bromo;

each R^{AB} is independently halo, alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;

each R^{AD} is independently hydroxy, alkoxy, haloalkyl, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;

Ring B is present or not present; wherein:

Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B—groups;

each R^B is independantly halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylcarbonyl, alkoxyalkoxy, alkylcarbonylaminoalkoxy, cycloalkyl, (cycloalkyl)alkyl, cycloalkyloxy, (cycloalkyl)alkoxy, —cycloalkylcarbonyl, —cycloalkylcarbonyloxy, —heterocycloalkyl optionally substituted with alkyl or alkylcarbonyl, (5-6-membered heterocycloalkyl-one)alkyl, (heterocycloalkyl)alkyl, or heterocycloalkylcarbonyl;


R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; where W is alkyl substituted with amino, —alkylamino, —dialkylamino, —alkylcarbonyloxy, —alkoxycarbonyl, —or phenylcarbonyloxy;

R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxycarbonyl;

provided that when Ring A is phenyl, Ring B is not present, and R¹ is ethyl, then Ring A cannot be substituted with trifluoromethoxy; and


optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.

18. —A compound of Formula (V):



wherein:

Ring C is selected from:



wherein the wavy lines (~~~~) indicate the points of attachment of the C₁-carbon to the carbonyl of C(O)-OR¹, and the C₂-carbon to O;

Ring A is cycloalkyl, C₈₋₁₁-spirocycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each is substituted with one or two R^{AB}-groups;

Ring B is present or not present; wherein

when Ring B is present, then Ring A is optionally substituted with one halo or alkyl;

when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:

- (i) one or two R^{AD}-groups;
- (ii) two groups selected from chloro or bromo; or
- (iii) one halo group and one group selected from the group consisting of haloalkoxy, (cycloalkyl)alkoxy, and (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;

or Ring A is unsubstituted C₈₋₁₁-spirocycloalkyl; unsubstituted dihydroxybenzodioxynyl; or unsubstituted tetrahydronaphthalene when R¹ is not hydrogen or ethyl;

each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; phenoxy optionally substituted with one or two halo; or (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;

each R^{AD} is independently hydroxy; alkoxy; haloalkyl; cycloalkyloxy; (cycloalkyl)alkoxy; or phenoxy optionally substituted with one or two halo;

Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;

each R^B is independently halo; cyano; alkyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; cycloalkyloxy; (cycloalkyl)alkoxy; cycloalkylcarbonyl;

~~cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl or halo; (5-6 membered heterocycloalkyl one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl;~~

~~R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxy carbonyl, phenylcarbonyloxy, aminocarbonyloxy, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy carbonyloxy, cycloalkylcarbonyloxy, N(R^{1A})C(O)R^{1B}, N(R^{1A})C(O)OR^{1B}, or N(R^{1A})C(O)NR^{1B}R^{1C}; wherein R^{1A}, R^{1B}, and R^{1C} are each independently hydrogen or C₁₋₆ alkyl;~~

~~R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy carbonyl;~~


~~provided:~~

~~(iii) when Ring A is phenyl, Ring B is not present, and R¹ is ethyl, then Ring A cannot be substituted with trifluoromethoxy; and~~

~~(iv) when Ring A is phenyl substituted with 1 R^{AD}, then R^{AD} cannot be meta-substituted trifluoromethyl; and~~


~~optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.~~

19. A compound of Formula (V):



wherein:

Ring C is selected from:



wherein the wavy lines (~~~~) indicate the points of attachment of the C₁ carbon to the carbonyl of C(O)OR¹, and the C₂ carbon to O;

Ring A is cycloalkyl, C₈₋₁₁-spirocycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each is substituted with one or two R^{AB}-groups;

Ring B is present or not present; wherein

when Ring B is present, then Ring A is optionally substituted with a group selected from halo, alkyl, alkoxy, cyano, hydroxy, and (cycloalkyl)alkoxy;

when Ring B is not present and Ring A is phenyl, then Ring A is substituted with:

(i) one or two R^{AD}-groups;

(ii) two groups selected from chloro or bromo; or

(iii) one halo group and one group selected from the group consisting of haloalkoxy, (cycloalkyl)alkoxy, and (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;

(iv) one cyano group and one (phenyl)alkoxy group, wherein the phenyl as part of the (phenyl)alkoxy group is optionally substituted with halo or haloalkoxy;

or Ring A is unsubstituted C₈₋₁₁-spirocycloalkyl; unsubstituted dihydroxybenzodioxynyl; or unsubstituted tetrahydronaphthalene when R¹ is not hydrogen or ethyl;

each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; phenoxy optionally substituted with one or two halo; or (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;

each R^{AD} is independently hydroxy; alkoxy; haloalkyl; cycloalkyloxy; (cycloalkyl)alkoxy; or phenoxy optionally substituted with one or two halo;

Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;

each R^B is independently halo; cyano; alkyl; hydroxyalkyl; alkylsulfonyl; aminosulfonyl; alkylaminosulfonyl; dialkylaminosulfonyl; haloalkyl; alkoxy; aminoalkoxy; alkylaminoalkoxy; dialkylaminoalkoxy; hydroxyalkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; cycloalkyloxy; (cycloalkyl)alkoxy wherein cycloalkyl group is optionally substituted with hydroxyalkyl; cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl or halo; (5-6-membered heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl; or 5-6 membered heteroaryl optionally substituted with alkyl wherein alkyl is optionally substituted with 1 or 2 groups independently selected from cycloalkyl and hydroxy; alkoxyalkyl; hydroxyalkyl; or hydroxycycloalkyl;

R^1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, —alkylamino, —dialkylamino, —alkylcarbonyloxy, —alkoxycarbonyl, phenylcarbonyloxy, —aminocarbonyloxy, —alkylaminocarbonyloxy, dialkylaminocarbonyloxy, —alkoxycarbonyloxy, —cycloalkylcarbonyloxy, — $N(R^{1A})C(O)R^{1B}$, — $N(R^{1A})C(O)OR^{1B}$, or — $N(R^{1A})C(O)NR^{1B}R^{1C}$; wherein R^{1A} , R^{1B} , and R^{1C} are each independently hydrogen or C_{1-6} -alkyl;


R^2 and R^3 are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxycarbonyl;

provided:

- (i) —when Ring A is phenyl, Ring B is not present, and R^1 is ethyl, then Ring A cannot be substituted with trifluoromethoxy; and
- (ii) —when Ring A is phenyl substituted with 1- R^{AD} , then R^{AD} cannot be meta-substituted trifluoromethyl; and


optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.

20. —A compound of Formula (VI):



wherein:

Ring C is selected from:




wherein the wavy lines (—) indicate the points of attachment of the C_1 -carbon to the carbonyl of $C(O)OR^1$, and the C_2 -carbon to S;

wherein:

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl other than thienyl or benzothiophenyl; each is substituted with one or two R^{AB} -groups;


~~provided when Ring A is phenyl and Ring B is not present, then Ring A is substituted with one or two R^{AE};~~
~~each R^{AB} is independently halo, alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, (cycloalkyl)alkoxy, or phenoxy optionally substituted with one or two halo;~~
~~each R^{AE} is independently halo, alkyl, haloalkyl, haloalkoxy, cycloalkyloxy, or (cycloalkyl)alkoxy;~~
~~Ring B is present or not present; wherein:~~
~~Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B groups;~~
~~each R^B is independantly halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylcarbonyl, alkoxyalkoxy, alkylcarbonylaminoalkoxy, cycloalkyl, (cycloalkyl)alkyl, cycloalkyloxy, (cycloalkyl)alkoxy, cycloalkylcarbonyl, cycloalkylcarbonyloxy, heterocycloalkyl optionally substituted with alkyl or alkylcarbonyl, (5-6-membered heterocycloalkyl-one)alkyl, (heterocycloalkyl)alkyl, or heterocycloalkylcarbonyl;~~
~~R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; where W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxycarbonyl, or phenylcarbonyloxy;~~
~~R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxycarbonyl;~~
~~provided that when Ring A is phenyl, then Ring B cannot be halo-substituted phenyl; and optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.~~

21. — A compound of Formula (VI):



wherein:

Ring C is selected from:



wherein the wavy lines () indicate the points of attachment of the C₁-carbon to the carbonyl of C(O)-OR¹, and the C₂-carbon to S;

Ring A is cycloalkyl, C₈₋₁₁-spirocycloalkyl, heterocycloalkyl, aryl, or heteroaryl other than thienyl or benzothiophenyl; each is substituted with one or two R^{AB}-groups;

provided when Ring A is phenyl and Ring B is not present, then Ring A is substituted with one or two R^{AE};

Ring B is present or not present; wherein:

each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; phenoxy optionally substituted with one or two halo; or (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;

each R^{AE} is independently halo; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; or (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;

Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;


each R^B is independently halo; cyano; alkyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; cycloalkyloxy; (cycloalkyl)alkoxy; cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl or halo; (5-6 membered heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl;

R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxy carbonyl, phenylcarbonyloxy, aminocarbonyloxy, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy carbonyloxy, cycloalkylcarbonyloxy, N(R^{1A})C(O)R^{1B}, N(R^{1A})C(O)OR^{1B}, or N(R^{1A})C(O)NR^{1B}R^{1C}; wherein R^{1A}, R^{1B}, and R^{1C} are each independently hydrogen or C₁₋₆-alkyl;

R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy carbonyl;


~~provided when Ring A is phenyl, then Ring B cannot be halo-substituted phenyl; and optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.~~

22. — A compound of Formula (VI):



wherein:

Ring C is selected from:



~~wherein the wavy lines (—) indicate the points of attachment of the C₁-carbon to the carbonyl of C(O)-OR¹, and the C₂-carbon to S;~~

~~Ring A is cycloalkyl, C₈₋₁₁-spirocycloalkyl, heterocycloalkyl, aryl, or heteroaryl other than thienyl or benzothiophenyl; each is substituted with one or two R^{AB}-groups;~~

~~provided when Ring A is phenyl and Ring B is not present, then Ring A is substituted with one or two R^{AE};~~

~~Ring B is present or not present; wherein:~~

~~each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; phenoxy optionally substituted with one or two halo; or (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;~~

~~each R^{AE} is independently halo; haloalkyl; haloalkoxy; cycloalkyloxy; (cycloalkyl)alkoxy; or (phenyl)alkoxy, wherein the phenyl is optionally substituted with halo;~~

~~Ring B, when present, is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B-groups;~~

~~each R^B is independently halo; cyano; alkyl; alkylsulfonyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; — cycloalkyloxy; — (cycloalkyl)alkoxy; — cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl;~~

alkylcarbonyl or halo; (5-6 membered heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; heterocycloalkylcarbonyl; or 5-6 membered heteroaryl;
 R^{1A} is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxy, carbonyl, phenylcarbonyloxy, aminocarbonyloxy, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, carbonyl, cycloalkylcarbonyloxy, $N(R^{1A})C(O)R^{1B}$, $N(R^{1A})C(O)OR^{1B}$, or $N(R^{1A})C(O)NR^{1B}R^{1C}$; wherein R^{1A} , R^{1B} , and R^{1C} are each independently hydrogen or C_{1-6} -alkyl;
 R^2 and R^3 are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy, carbonyl;
provided when Ring A is phenyl, then Ring B cannot be halo substituted phenyl; and optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.

23. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-22, wherein Ring A is C_{3-7} -cycloalkyl, 5-6 membered heterocycloalkyl, or phenyl.

24. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-23, wherein Ring A is C_{3-7} -cycloalkyl.

25. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-23, wherein Ring A is 5-6 membered heterocycloalkyl.

26. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-23, wherein Ring A is phenyl.


27. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-26, wherein R^1 is hydrogen or W.

28. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-27, wherein R^1 is hydrogen.


29. ~~The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-27, wherein R¹ is W.~~

30. ~~The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-29, wherein R² and R³ are independently hydrogen.~~

31. ~~The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-30, wherein ring C is:~~



32. ~~The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of any one of claims 1-30, wherein ring C is:~~



33. ~~A compound selected from the group consisting of compounds in Table 1, Table 2, and Table 4; optionally as a tautomer, a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.~~

34. ~~A compound selected from Compounds 1-168, or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.~~


35. ~~A compound selected from the group consisting of Compounds 169-375, or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.~~

~~36.—A compound selected from the group consisting of Compounds 376-486, or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.~~

~~37.—A compound selected from the group consisting of compounds 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 185, 186, 187, 188, 189, 190, 194, 195, 196, 197, 198, 199, 200, 201, 203, 204, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272-1, 272-2, 273, 274, 275, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 295, 297, 298, 299, 300, 301, 303, 304, 305, 306, 307, 308-1, 308-2, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 367, 368, 369, 370, 373, and 375, or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.~~

~~38.—A compound selected from the group consisting of compounds 376, 377, 379, 380, 381, 382, 383, 384, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442-1, 442-2, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, and 486, or a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.~~


~~39.—A compound of Formula (VIII):~~



(VIII),

wherein:

ring C is selected from:



wherein the wavy lines (~~~~) indicate the points of attachment of the C₁ carbon to the carbonyl of C(O)-OR¹, and the C₂ carbon to L;

L is a bond, CH₂, CH₂CH₂, O, or CH₂O;

X is N or CH;

R^{1D} and R^{1E} are each independently H or hydroxy;

m is 1, 2, or 3;

n is 0, 1, 2, or 3;

Ring A and Ring B are each independently C₃₋₇-cycloalkyl, 5-6 membered heterocycloalkyl, aryl or heteroaryl, optionally substituted with halo, haloalkyl or phenyl; wherein phenyl is optionally substituted with halo, haloalkyl, or haloalkoxy; and optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.

40. The compound of claim 39, wherein the compound is selected from the group consisting of compounds 294, 296, 366, 372, 374, 378, and 385, or optionally as a tautomer, a single stereoisomer or mixture of stereoisomers thereof and additionally optionally as a pharmaceutically acceptable salt thereof.

41. A pharmaceutical composition comprising a compound of any one of claims 1-40, optionally as a single stereoisomer, or mixtures of stereoisomers, and additionally optionally as a pharmaceutically acceptable excipient.

~~42. A method of treating a disease or disorder associated with a defect in glyoxylate metabolism comprising administering to a patient suffering from such disease or disorder a compound or pharmaceutically acceptable salt thereof of any one of claims 1-40 or the pharmaceutical composition of claim 41.~~


~~43. The method of claim 42, wherein the disease or disorder is a primary hyperoxaluria.~~

~~44. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-40 or the pharmaceutical composition of claim 41, for use as a medicament.~~

~~45. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-40 or the pharmaceutical composition of claim 41, for use in a method of treating a disease or disorder associated with a defect in glyoxylate metabolism.~~


~~46. The compound or pharmaceutically acceptable salt thereof for use or the pharmaceutical composition for use of claim 45, wherein the disease or disorder is primary hyperoxaluria.~~

1. A compound of Formula (I):



wherein:

ring C is selected from:



wherein the wavy lines (~~~~~) indicate the points of attachment of the C₁ carbon to the carbonyl of C(O)-OR¹, and the C₂ carbon to L;

L is S;

Ring A is C₃₋₈ cycloalkyl, C₈₋₁₁ spirocycloalkyl, 5-8 membered heterocycloalkyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thienyl, phenyl, naphthyl, indanyl, tetrahydronaphthyl, dihydronaphthyl, pyridyl, indolyl, benzothiazolyl, quinoliny, isoquinoliny, indoliny, isoindoliny, tetrahydroquinoliny, dihydroisoquinoliny, tetrahydroisoquinoliny, 2,3-dihydrobenzo[b][1,4]dioxiny, or tetrahydro-methanonaphthaleny;

wherein Ring A is optionally substituted with one or two groups independently selected from halo, alkyl, alkoxy, cyano, hydroxy, haloalkoxy, (cycloalkyl)alkoxy, and cycloalkyl;

Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B groups;

each R^B is independently halo; cyano; alkyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; cycloalkyloxy; (cycloalkyl)alkoxy; cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl or a halo; (5-6-membered heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl;

R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxy carbonyl, phenylcarbonyloxy, aminocarbonyloxy, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy carbonyloxy, cycloalkylcarbonyloxy, -N(R^{1A})C(O)R^{1B}, -N(R^{1A})C(O)OR^{1B}, or -N(R^{1A})C(O)NR^{1B}R^{1C}; wherein R^{1A}, R^{1B}, and R^{1C} are each independently hydrogen or C₁₋₆ alkyl;

R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy carbonyl;

provided when Ring A is phenyl, then Ring B cannot be halo-substituted phenyl;

and

optionally a single stereoisomer or mixture of stereoisomers thereof and additionally optionally a pharmaceutically acceptable salt thereof.

2. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein


Ring A is C₃₋₇ cycloalkyl, 5-6 membered heterocycloalkyl, phenyl, or naphthyl, wherein Ring A is optionally substituted with halo or haloalkoxy;

Ring B is cycloalkyl, heterocycloalkyl, phenyl, tetrahydronaphthyl, tetrahydroquinoliny, quinoliny, or, isoquinoliny; wherein each Ring B is optionally substituted with one or two R^B groups;

each R^B is independently halo; cyano; haloalkyl; haloalkoxy; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkoxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl or halo; or (5-6-membered heterocycloalkyl-one)alkyl; and


R¹ is hydrogen or W; wherein W is alkyl substituted with alkylcarbonyloxy, dialkylaminocarbonyloxy, cycloalkylcarbonyloxy, or phenylcarbonyloxy.

3. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein the compound is a compound of Formula (VI):



wherein:

Ring C is selected from:



wherein the wavy lines (~~~~~) indicate the points of attachment of the C₁ carbon to the carbonyl of C(O)-OR¹, and the C₂ carbon to S;

Ring A is C₃₋₈ cycloalkyl, C₈₋₁₁ spirocycloalkyl, 5-8 membered heterocycloalkyl, phenyl, naphthyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, pyridyl, indolyl, quinoliny, isoquinoliny, indoliny, isoindoliny, dihydroisoquinoliny, tetrahydroisoquinoliny, or 2,3-dihydrobenzo[b][1,4]dioxiny; each is substituted with one or two R^{AB} groups;

Ring B is present; wherein:

each R^{AB} is independently halo; alkyl; hydroxy; alkoxy; haloalkoxy; (cycloalkyl)alkoxy;

Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each is optionally substituted with one or two R^B groups;

each R^B is independently halo; cyano; alkyl; haloalkyl; alkoxy; haloalkoxy; alkylcarbonyl; alkoxyalkoxy; aminocarbonyl; alkylcarbonylaminoalkoxy; cycloalkyl; (cycloalkyl)alkyl; cycloalkyloxy; (cycloalkyl)alkoxy; cycloalkylcarbonyl; cycloalkylcarbonyloxy; heterocycloalkyl optionally substituted with 1 or 2 alkyl, alkylcarbonyl or halo; (5-6 membered heterocycloalkyl-one)alkyl; (heterocycloalkyl)alkyl; or heterocycloalkylcarbonyl;

R¹ is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, or W; wherein W is alkyl substituted with amino, alkylamino, dialkylamino, alkylcarbonyloxy, alkoxy carbonyl, phenylcarbonyloxy, aminocarbonyloxy, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy carbonyloxy, cycloalkylcarbonyloxy, -N(R^{1A})C(O)R^{1B}, -N(R^{1A})C(O)OR^{1B}, or -N(R^{1A})C(O)NR^{1B}R^{1C}; wherein R^{1A}, R^{1B}, and R^{1C} are each independently hydrogen or C₁₋₆ alkyl;

R² and R³ are independently hydrogen, alkyl, phenyl, benzyl, or alkoxy-substituted benzyl; wherein the alkyl is optionally substituted with halo, alkoxy, haloalkoxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, or heterocycloalkylcarbonyloxy optionally substituted with alkoxy carbonyl;

provided when Ring A is phenyl, then Ring B cannot be halo-substituted phenyl.

4. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein Ring A is C₃₋₇ cycloalkyl, 5-6 membered heterocycloalkyl, or phenyl.

5. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 4, wherein Ring A is C₃₋₇ cycloalkyl.

6. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 4, wherein Ring A is 5-6 membered heterocycloalkyl.

7. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 4, wherein Ring A is phenyl.

8. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein R¹ is hydrogen or W.

9. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein R² and R³ are independently hydrogen.

10. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein Ring B is cycloalkyl.

11. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein Ring B is heterocycloalkyl.

12. The compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1, wherein Ring B is heteroaryl.

13. A compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of compounds

ethyl 4-((4-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylate,
4-((4-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((5-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
5-((3-(4-methylpiperazin-1-yl)phenyl)thio)-1H-1,2,3-triazole-4-carboxylic acid,
4-((4-(piperidin-1-yl)phenyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((2-(3,4-dichlorophenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
cyclobutyl 4-((4-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylate,
4-((4-(4-methylpiperazin-1-yl)phenyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
isopropyl 4-((4-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylate,
4-((5-(4-bromophenyl)pyridin-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((5-(3,4-dichlorophenyl)-4H-1,2,4-triazol-3-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4'-methoxy-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4-(3-chloro-4-methoxyphenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
methyl 4-((4-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylate,
4-((4-(3-chloro-4-cyclopropoxyphenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
cyclopropyl 4-((4-(3,4-dichlorophenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylate,
4-((6-(3,4-dichlorophenyl)pyridin-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((2-(4-chloro-3-methoxyphenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

4-((2-(4-chloro-3-isopropoxyphenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
5-((2-(3-chloro-4-methoxyphenyl)thiazol-4-yl)thio)-1-(4-methoxybenzyl)-1H-1,2,3-triazole-
4-carboxylic acid,
4-((2-(3-chloro-4-methoxyphenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((2-(2,4-dichlorophenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((2-(3-chloro-4-isopropoxyphenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((5-(3,4-dichlorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl)thio)-1H-1,2,3-triazole-5-
carboxylic acid · 2,2,2-trifluoroacetate,
4-((4'-chloro-3'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
4-((2'-chloro-3'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
4-((3'-chloro-4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
methyl 4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate,
4-((2-(3,4-dichlorophenyl)-1-methyl-1H-imidazol-5-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
4-((5-(3,4-dichlorophenyl)thiophen-3-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
2-(dimethylamino)ethyl 4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-
triazole-5-carboxylate,
N,N,N-trimethyl-2-((4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-
carbonyl)oxy)ethan-1-aminium iodide,
4-((2-(3-chloro-4-(trifluoromethoxy)phenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
methyl 4-((2-(3-chloro-4-(trifluoromethoxy)phenyl)thiazol-4-yl)thio)-1H-1,2,3-triazole-5-
carboxylate,
4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4-(3-chloro-4-(trifluoromethoxy)phenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
methyl 4-((4-(3-chloro-4-(trifluoromethoxy)phenyl)thiazol-2-yl)thio)-1H-1,2,3-triazole-5-
carboxylate,
oxetan-3-yl 4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-
carboxylate,

1-((pivaloyloxy)methyl)-4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

1-((isobutyryloxy)methyl)-4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

(pivaloyloxy)methyl 4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate,

(isobutyryloxy)methyl 4-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate,

4-((3'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

4-((4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,

4-((3'-(cyclopropylmethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,

4-(((4-(1-methyl-1,2,3,4-tetrahydroquinolin-6-yl)phenyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,

(isobutyryloxy)methyl 4-((4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate,

4-((3'-cyclohexyl-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

(benzoyloxy)methyl 4-((4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate,

(propionyloxy)methyl 4-((4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate,

4-((3-(4-(trifluoromethoxy)phenyl)cyclopentyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

((cyclohexanecarbonyl)oxy)methyl 4-((4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylate 2,2,2-trifluoroacetate,

4-((4'-(4,4-difluoropiperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,

4-((5-(trifluoromethoxy)-2,3-dihydro-1H-inden-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

4-((4-(5-(trifluoromethoxy)pyridin-2-yl)phenyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,

4-((1-(3,4-dichlorophenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,

4-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

4-((1-(3,5-dichlorophenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4-(3-(trifluoromethoxy)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4-(3-(trifluoromethyl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((1-(2,5-dichlorophenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((cis)-4-(3,5-dichlorophenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((cis)-4-(4-(trifluoromethyl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((cis)-4-(3-chloro-5-(trifluoromethoxy)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-
carboxylic acid,
4-((1-(3-chloro-5-(trifluoromethoxy)phenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-
carboxylic acid,
4-((4-(4,4-difluoropiperidin-1-yl)phenyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-
trifluoroacetate,
4-((4-(3-(piperidin-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-
trifluoroacetate,
4-(((cis)-4-(4-(4-methylpiperazin-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
4-((2-chloro-4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((1-(4-cyanophenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-
trifluoroacetate,
4-(((cis)-4-(3,4-dichlorophenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-
trifluoroacetate,
4-((1-(3-chloro-4-(trifluoromethoxy)phenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-
carboxylic acid,
4-(((cis)-4-(4-(pyrrolidin-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid
2,2,2-trifluoroacetate,
4-(((cis)-4-(4-(trifluoromethoxy)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((4'-(2-methylpiperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid
2,2,2-trifluoroacetate,
4-(((cis)-4-(4-cyanophenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((3'-chloro-4'-(piperidin-1-yl)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic
acid,
4-((1-(5-chloro-2-(trifluoromethoxy)phenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-
carboxylic acid,
4-((4'-cyano-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,

4-((4'-chloro-2-(cyclopentylmethoxy)-[1,1'-biphenyl]-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-((1-(2-chloro-5-(trifluoromethoxy)phenyl)piperidin-4-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((trans)-4-(quinolin-6-yl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((trans)-4-(2-chloro-5-(trifluoromethoxy)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((trans)-3-(4-cyanophenyl)cyclobutyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((trans)-4-(4-(trifluoromethoxy)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((3aR,5s,6aS)-2-(3,4-dichlorophenyl)octahydrocyclopenta[c]pyrrol-5-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((trans)-4-(5-chloro-2-(trifluoromethoxy)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid,
4-(((trans)-4-(4-(piperidin-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((trans)-3-(4-(piperidin-1-yl)phenyl)cyclobutyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((trans)-4-(4-(methylsulfonyl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((cis)-4-(3-chloro-4-(piperidin-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((trans)-4-(3-chloro-4-(piperidin-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate,
4-(((trans)-4-(4-(1H-pyrazol-1-yl)phenyl)cyclohexyl)thio)-1H-1,2,3-triazole-5-carboxylic acid 2,2,2-trifluoroacetate, and
4-(((cis-3a,6a)-5-(4-(trifluoromethoxy)phenyl)octahdropentalen-2-yl)thio)-1H-1,2,3-triazole-5-carboxylic acid.

14. A pharmaceutical composition comprising the compound, single stereoisomer or mixture of stereoisomers or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable excipient.